a phase III, randomized, open-label trial evaluating the efficacy of atezolizumab administered concomitantly with bladder instillations of BCG (Bacille Calmette-Guérin) for one year in patients with non-muscle-invasive bladder cancer at high risk of recurrence and who have not been previously treated with BCG. ALBAN